Navigation Links
La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial

SAN DIEGO, March 20, 2007 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company today announced updated interim antibody reduction data for the Phase 3 trial of Riquent(R) (abetimus sodium), its drug candidate for systemic lupus erythematosus ("lupus" or "SLE"). The updated analyses reinforce the previous conclusion that there is a definitive and significant dose response between the 100 mg, 300 mg and 900 mg doses of Riquent compared with placebo (p=0.0001). These interim data were initially announced March 8, 2007.

Dose Dependent Antibody Reduction

The minor changes to the data show a greater reduction from baseline in antibody levels in patients treated with Riquent. The median percent reductions were 100 mg: 18%; 300 mg: 28%; 900 mg: 46% at week 8. In parallel, there was less of an increase above baseline in the antibody levels for the placebo group. As a result, the reductions in median antibody levels between the Riquent treatment groups and the placebo treatment group at week 8 were 100 mg: 30%; 300 mg: 40%; 900 mg: 58% (p=0.0032, p<0.0001, p<0.0001 respectively).

Approximately three times as many patients treated with 900 mg of Riquent (42%) had at least a 50% or greater antibody reduction at week 8 compared with patients treated with 100 mg (13%). Patients reached their maximum reduction after four weeks of treatment at which time separation between doses was also seen.

The analyses assessed the impact of treatment with Riquent on reducing antibodies to dsDNA in 101 patients by measuring the percent of antibody reduction from baseline compared with placebo following weekly treatment with 100 mg, 300 mg or 900 mg of Riquent or placebo. All demographics and baseline characteristics were comparable across dosing groups and there were 16 to 30 patients per treatment group.

Consistent Antibody Reductions

Published data from earlier La Jolla studies indicated tha
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:3/31/2015)... -- Accelerated orthodontic treatment will be a featured ... Annual Session, May 15-19, as seven of the ... ® . Manufactured by OrthoAccel ® Technologies, ... a FDA-cleared, Class II medical device that speeds ... percent with just 20 minutes of daily use. ...
(Date:3/31/2015)... -- SCILEX Pharmaceuticals, Inc., a company engaged in the development ... pain, today announced that ITOCHU CHEMICAL FRONTIER Corporation (ICF, ... ITOCHU Corporation ( Tokyo : 8001; OTC-PINK: ... trading companies) in Japan , has ... closely with SCILEX as an advisor and development partner ...
(Date:3/31/2015)... , March 31, 2015  SynCardia Systems, Inc. has ... (IDE) clinical study on the effective use of its ... The FDA approval will ... as 30 heart failure patients. Patients enrolled in this ... as a bridge to a donor heart transplant. ...
Breaking Medicine Technology:Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 2Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 3SCILEX Pharmaceuticals Announces Strategic Investment By ITOCHU CHEMICAL FRONTIER Corporation 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 3FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 4
... patients will be tested,to determine the prevalence of ... major cooperative effort between the Alpha-1 Foundation,and the ... principal investigator is Robert A. Sandhaus, MD, PhD, ... and Research Center,in Denver. Sandhaus is also the ...
... Dec. 6 DURECT Corporation,(Nasdaq: DRRX ... III trial for Remoxy,had successfully met its ... the U.S. Food and Drug Administration (FDA) ... investigational drug based on,DURECT,s patented ORADUR(TM) technology, ...
Cached Medicine Technology:Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1 2Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1 3Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 2Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 3Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 4
(Date:4/1/2015)... Amada Senior Care , premier provider ... opened a new office in Rocky Mount, NC – their ... Bissett decided to make the move to senior care with ... 20 years of experience in management and consulting. Their grand ... , When asked what makes Amada different from other homecare ...
(Date:4/1/2015)... TCS Healthcare Technologies (TCS), a leading ... management and population health arenas, is pleased to announce ... which is fully integrated with the ACUITY platform. , ... p.m. ET, will be led by Jeff Frater, RN, ... explore the feature-rich portal as well as the importance ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Enterprise ... 501 Global Edition, a distinguished list and report ... (MSPs). The complete 501 list is currently available ... ,     The top ranked MSPs in North America ... East and Africa ,     The top MSPs ...
(Date:3/31/2015)... 31, 2015 As the demand for ... pledging to have a mobile-friendly website online sometime during ... of Chunk Fitness’ continued commitment to bring the best ... base. All of the same great fitness information at ... be substantially easier to read while browsing on a ...
(Date:3/31/2015)... Francisco, CA (PRWEB) March 31, 2015 ... their upcoming events. The schedule for April will include ... follows: , New Student Orientation, 9-11 a.m. April 6, ... held in Room D at the Pioneer Square Campus ... & Financial Aid, 12:30-1:30 p.m. April 14, Students will ...
Breaking Medicine News(10 mins):Health News:Amada Senior Care Expands to Eastern North Carolina 2Health News:TCS Healthcare Technologies Releases Acuity Connect 2Health News:TCS Healthcare Technologies Releases Acuity Connect 3Health News:Penton Technology Names Enterprise Integration to the MSPmentor 501 Global Edition 2Health News:Penton Technology Names Enterprise Integration to the MSPmentor 501 Global Edition 3Health News:ACTCM Announces April Event Schedule 2
... , ... ... ... ...
... ... the third leading cause of mortality in the U.S., according to the Centers for ... ... and costly problem. The culprit…Hospital Acquired Infections (HAIs) and they have generated much attention ...
... Previous studies have explored the effect of periodontal ... infant prematurity. In a study titled "Risk of ... lead researcher M. Jeffcott, and colleagues S. Parry ... Pennsylvania, Philadelphia) and G. Macones (Washington University, St. ...
... of the Democrats, supermajority necessary to pass comprehensive ... to promote greater efficiency in the medical delivery ... would accelerate delivery system change but would be ... congressional proposals that provide new authority for the ...
... dirty air and heart problems , THURSDAY, March 4 ... particles caused by traffic has been linked to an ... the new report, researchers analyzed data from 939 participants ... four years between 1995 and 2006. A computer model ...
... study finds that weather warmer than 75 degrees poses added ... suggests that cocaine overdose deaths in New York City go ... weekly temperature goes past 75 degrees Fahrenheit. , The ... , are based on death statistics in the city from ...
Cached Medicine News:Health News:Christiana Care Health System Wins National Award for Innovation 2Health News:Christiana Care Health System Wins National Award for Innovation 3Health News:24x7 Infection Control, Inc. Announces World's First, Modern &#8220;Shield&#8221; Against Microbial Contamination 2Health News:24x7 Infection Control, Inc. Announces World's First, Modern &#8220;Shield&#8221; Against Microbial Contamination 3Health News:Experts support new federal center for Medicare and Medicaid innovation 2Health News:Years of Exposure to Traffic Pollution Raises Blood Pressure 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: